United States · Research startup
United States · NGM Biopharmaceuticals
NGM Biopharmaceuticals Inc.
Funding reportedLast round: Series A
About NGM Biopharmaceuticals
NGM Biopharmaceuticals Inc.
(NGM Bio) is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2007, the company focuses on discovering and developing innovative medicines for serious health conditions. NGM Bio is currently concentrating on its lead product, NGM120, a GDF15/GFRAL antagonist antibody, which is in Phase 2 clinical trials for hyperemesis gravidarum and cancer cachexia. The company has a diverse pipeline that includes therapeutics targeting various diseases such as cardio-metabolic, liver, oncologic, and retinal conditions. NGM Bio employs a biology-centric drug discovery approach, integrating complex disease biology with protein engineering to advance its biologic candidates. Collaborating with Merck Sharp & Dohme Corp. and Merck & Co., Inc., NGM Bio aims to develop novel treatments for unmet medical needs, particularly in the areas of severe pregnancy-related nausea and cancer-related weight loss.
What company datasets say NGM Biopharmaceuticals raised
Funding, as reported
Founders and team
From NGM Biopharmaceuticals's own website and the SEC filings it signed: 5 on the team.
- Diana Peng BockusChief Executive Officer
- Tianny SzetoVice President, Finance
- William ChangVice President, Clinical Operations
- Jin-Long ChenExecutive Officer, Directori
- William J. RieflinExecutive Officer, Directori
On the board, as filediDavid V. GoeddelDavid V. SchnellMark V. LeschlyMcHenry T. TichenorPeter V. Svennilson
On 2 portfolio pages
Investors who name them
Each firm lists NGM Biopharmaceuticals on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
marketing strategybiologic drug candidateshealth careuser experienceliver disease treatmentsbiotech therapeuticsbiotechnology researchbiological pathwayhealthcare providershealthcare solutionscollaborationpartnership opportunitiesin-house innovationmedical researchoncology drugshealthcare data
Built with from their website
AdobeGoogle Tag ManagerUserWayWordPress.orgGoogle WorkspaceGemViewport MetawebpackC3.jsSophos Email
+8 more
Google MeetPriority HintsReactSophos CentralMobile FriendlyGreenhouseVercelOpen Graph
- Sector
- Research
- Industry code
- NAICS 541714, 325414, SIC 2834
- Region
- California
- Revenue
- $3.6M a year, as listed
- Full record
- Every detail in the company directory
Research in United States
Startups like it
OpenAISan Francisco · founded 2011Raised
Retro BiosciencesRedwood City · founded 2021Raised
NewLimitSouth San Francisco · founded 2022Raised
PathosNew York · founded 2022Raised
Colossal BiosciencesDallas · founded 2021Raised
OratomicSouth PasadenaRaised
Beeline MedicinesStamford · founded 2025Raised
Element BiosciencesSan Diego · founded 2017Raised
Is this your company?
Add your raise, your deck and your story, and put NGM Biopharmaceuticals in front of investors. Or tell us what we have wrong.